Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 16, 2025

Immunotherapy in older adults with gynecologic cancers: rethinking age as a limiting factor.

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYoshio YoshidaMOMakoto OrisakaDIDaisuke Inoue

Discussion

Loading...

Member takes

Overview

This review highlights the impact of age on immune checkpoint inhibitors in older adults, suggesting tailored treatment approaches may improve outcomes.

Key Points

  • Immunotherapy shows promising efficacy in older adults with gynecologic cancers, highlighting the need to reassess age as a limiting factor.
  • Clinical data indicates that immune checkpoint inhibitors can provide significant survival benefits, often comparable to younger patients.
  • Observational review considers age-related immune changes, tumor microenvironments, and the role of biomarkers in treatment efficacy assessments.
  • Management of immune-related adverse events is crucial, but their overall incidence in older adults is not consistently higher than in younger cohorts.

Cite This Study

Yoshida et al. (2025) studied this question.

synapsesocial.com/papers/68af2b68cf1dd9ea359e4ebehttps://doi.org/10.1080/14656566.2025.2548887
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune checkpoint inhibition in the context of aging2025
  2. 2Effect of organism aging on the development of anti-PD-(L)1 therapy-associated adverse events2025
  3. 3Efficacy of immunotherapy in older patients with triple-negative breast cancer: a systematic review2025
  4. 4Age-related survival disparities in advanced renal cell carcinoma following immune checkpoint inhibitor adoption using SEER and meta-analysis2025
  5. 5Do age and performance status matter? A systematic review and network meta-analysis of immunotherapy studies in untreated advanced/metastatic non-oncogene addicted NSCLC2025